Literature DB >> 7082587

A new familial variant of antithrombin III: 'antithrombin III Paris'.

M Wolf, C Boyer, J M Lavergne, M J Larrieu.   

Abstract

A 59-year-old woman presented a recurrent history of thromboembolism. A qualitative defect of antithrombin III (AT III) was suggested by the discrepancy between a normal amount of AT III antigen and a decreased heparin cofactor activity. Six members of the same family showed a similar defect although clinically asymptomatic. The qualitative abnormality of AT III was confirmed by two-dimensional immunoelectrophoresis. In the absence of heparin, a single peak was obtained with both control and patients' plasmas. In the presence of heparin, two peaks of AT III were observed in the patients' plasmas: the mobility of one peak was similar to that of the control, whereas the other showed a decreased mobility, suggesting a lack of binding to heparin. The two populations of AT III were separated by affinity chromatography on heparin-agarose. 50% of the patients' AT III bound to the agarose beads. The remainder, recovered in the supernatant, migrated in two-dimensional immunoelectrophoresis as a single peak with the same mobility in the presence or absence of heparin, and was devoid of heparin cofactor activity. This familial AT III variant characterized a reduced affinity for heparin is tentatively named 'Antithrombin III Paris'.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082587     DOI: 10.1111/j.1365-2141.1982.tb02782.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Associated von Willebrand disease as a possible cause of lack of thrombosis in an AT III abnormality (AT III Trento).

Authors:  A Girolami; M G Cappellato; M A Vicarioto; S Casonato; F Marafioti
Journal:  Blut       Date:  1986-01

2.  Evidence linking familial thrombosis with a defective antithrombin III gene in two British kindreds.

Authors:  S H Sacks; J M Old; S T Reeders; D J Weatherall; A S Douglas; J H Winter; C R Rizza
Journal:  J Med Genet       Date:  1988-01       Impact factor: 6.318

3.  Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.

Authors:  J Y Borg; M C Owen; C Soria; J Soria; J Caen; R W Carrell
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

4.  Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity.

Authors:  D Stern; P Nawroth; J Marcum; D Handley; W Kisiel; R Rosenberg; K Stern
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

5.  Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation.

Authors:  P Molho-Sabatier; M Aiach; I Gaillard; J N Fiessinger; A M Fischer; G Chadeuf; E Clauser
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.